Get the Stockscreener App
6.12
1.66%
0.10
Lexeo Therapeutics Inc stock is traded at $6.12, with a volume of 231.72K.
It is up +1.66% in the last 24 hours and down -44.96% over the past month.
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.
See More
Previous Close:
$6.02
Open:
$5.99
24h Volume:
231.72K
Relative Volume:
0.59
Market Cap:
$202.36M
Revenue:
-
Net Income/Loss:
$-62.31M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-19.90%
1M Performance:
-44.96%
6M Performance:
-55.56%
1Y Performance:
-46.03%
1-Day Range:
$5.77
$6.25
1-Week Range:
$5.77
$8.52
52-Week Range:
$5.77
$22.33
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Name
Lexeo Therapeutics Inc
Sector
Industry
Phone
(212) 547-9879
Address
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| LXEO | 6.12 | 202.36M | 0 | -62.31M | 0 | 0.00 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Lexeo Therapeutics Inc Stock (LXEO) Latest News
Lexeo stock hits 52-week low at $5.8 amid market challenges - Investing.com India
Here's Why We're Watching Lexeo Therapeutics' (NASDAQ:LXEO) Cash Burn Situation - Yahoo Finance
(LXEO) Trading Advice - Stock Traders Daily
FY2024 EPS Forecast for Lexeo Therapeutics Cut by Analyst - MarketBeat
FY2024 Earnings Estimate for LXEO Issued By Leerink Partnrs - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Expected to Rise, HC Wainwright Analyst Says - Defense World
HC Wainwright Has Negative Estimate for LXEO FY2024 Earnings - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Expected to Rise, Chardan Capital Analyst Says - Defense World
Lexeo Therapeutics Advances Cardiac Portfolio Amid Financial Report - TipRanks
Janus Henderson Group PLC's Strategic Acquisition in Lexeo Thera - GuruFocus.com
Eventide Asset Management's Strategic Reduction in Lexeo Therape - GuruFocus.com
Lexeo Therapeutics Strengthens Leadership with New Board Appointment - TipRanks
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results - The Manila Times
Lexeo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lexeo Therapeutics Secures FDA Alignment, Reports $157M Cash Position Despite Q3 Loss | LXEO Stock News - StockTitan
Lexeo stock hits 52-week low at $7.54 amid market challenges By Investing.com - Investing.com South Africa
Lexeo stock hits 52-week low at $7.54 amid market challenges - Investing.com India
When (LXEO) Moves Investors should Listen - Stock Traders Daily
Analysts Set Lexeo Therapeutics, Inc. (NASDAQ:LXEO) PT at $22.14 - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Earns Buy Rating from HC Wainwright - MarketBeat
Lexeo shares dip on early data with Alzheimer's gene therapy - pharmaphorum
Lexeo reports positive Alzheimer's drug trial results - Investing.com India
Lexeo reports positive Alzheimer's drug trial results By Investing.com - Investing.com South Africa
Lexeo Therapeutics Announces Positive Interim Data for - GlobeNewswire
How now, tau? ‘Newer science’ shines in Lexeo Alzheimer’s data - BioWorld Online
Lexeo Therapeutics Sees Positive Results for Alzheimer's Disease Treatment - MarketWatch
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to - The Bakersfield Californian
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference - StockTitan
Lexeo Therapeutics’ (LXEO) “Buy” Rating Reiterated at Chardan Capital - Defense World
(LXEO) Investment Analysis - Stock Traders Daily
Novo Holdings A S Trims Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Lexeo Therapeutics' (LXEO) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference - The Manila Times
Lexeo Therapeutics to Present New Interim Data from Phase - GlobeNewswire
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference - StockTitan
R. Nolan Townsend - Crain's New York Business
(LXEO) Proactive Strategies - Stock Traders Daily
Suppliers Pushing Novel Analytical Methods Testing Forward - BioProcess Online
Insider Selling: Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Sells 5,000 Shares of Stock - MarketBeat
Lexeon therapeutics CEO sells $40,495 in shares - Investing.com
Lexeo Therapeutics (NASDAQ:LXEO) Files 8-K Disclosing Change in Directors or Principal Officers - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Long Term Trading Analysis for (LXEO) - Stock Traders Daily
Lexeo Therapeutics' SWOT analysis: gene therapy stock poised for growth - Investing.com India
Novo Holdings A S Reduces Stock Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Lexeo Therapeutics' SWOT analysis: gene therapy stock poised for growth By Investing.com - Investing.com UK
Can you now get a good deal on Lexicon Pharmaceuticals Inc’s shares? - US Post News
Aurobindo to acquire 49% stake in GLS Pharma for Rs 22.5 crore - The Economic Times
LXP Industrial Trust (NYSE:LXP) PT Raised to $11.00 at Evercore ISI - Defense World
Lexicon Pharmaceuticals President and COO Jeffrey Wade to step down - The Business Journals
How Analyst Ratings Affect Leap Therapeutics Inc Inc. (LPTX) Price Performance - The InvestChronicle
Lexeo Therapeutics Inc Stock (LXEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):